drugset / Trial / NCT00098046

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

NCT00098046

Phase 3 Completed 76 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is usually a self-limiting illness characterized by fever and a rash. Serious complications can include secondary bacterial infections, pneumonia, and encephalitis. Anti-viral treatment is not a standard of care in immunocompetent children, but is recommended whenever a risk of complication exists. This study will evaluate the safety and blood levels of a new formulation of famciclovir in children 1-12 years of age.

Timeline

Start
2005-07
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Famciclovir Small molecule 12.5 mg/kg Oral
Subject Famciclovir Small molecule 500 mg Oral